Evidence map›Paper›PMID 41994491›Full record

ArticleJournal of the Endocrine Society2026

Associations of selected atypical non-neuroendocrine cancers with multiple endocrine neoplasia type 1.

Iina Yliaska, Joona Tapio, Timo A Kumpula, Vesa-Matti Pohjanen, Tapani Ebeling, Olavi Ukkola, Outi Kuismin, Minna Koivikko, Katri Pylkäs, Pasi I Salmela

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Iina YliaskaMedical Research Center Oulu, Oulu University Hospital, Research Unit of Biomedicine and Internal Medicine, University of Oulu, Oulu FIN-90029, Finland.ORCID https://orcid.org/0000-0003-1164-5640
Joona TapioResearch Unit of Extracellular Matrix and Hypoxia, Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu FIN-90014, Finland.
Timo A KumpulaLaboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit, Medical Research Center Oulu and Biocenter Oulu, University of Oulu, Oulu FIN-90014, Finland.
Vesa-Matti PohjanenCancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu FIN-90029, Finland.
Tapani EbelingMedical Research Center Oulu, Oulu University Hospital, Research Unit of Biomedicine and Internal Medicine, University of Oulu, Oulu FIN-90029, Finland.
Olavi UkkolaMedical Research Center Oulu, Oulu University Hospital, Research Unit of Biomedicine and Internal Medicine, University of Oulu, Oulu FIN-90029, Finland.
Outi KuisminDepartment of Clinical Genetics, Research Unit of Clinical Medicine, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu FIN-90029, Finland.
Minna KoivikkoMedical Research Center Oulu, Oulu University Hospital, Research Unit of Biomedicine and Internal Medicine, University of Oulu, Oulu FIN-90029, Finland.
Katri PylkäsLaboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit, Medical Research Center Oulu and Biocenter Oulu, University of Oulu, Oulu FIN-90014, Finland.
Pasi I SalmelaMedical Research Center Oulu, Oulu University Hospital, Research Unit of Biomedicine and Internal Medicine, University of Oulu, Oulu FIN-90029, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: Multiple endocrine neoplasia type 1 (MEN1) is a hereditary tumor predisposing syndrome, characterized by typical neuroendocrine tumors in parathyroid, pituitary, and endocrine pancreas tissues ("3P"). MEN1 is also associated with non-neuroendocrine cancers, which are less studied. Objective: To assess the prevalence of certain non-neuroendocrine cancers associated with MEN1 in Finnish patients and compare the findings with a local control population. Design: Retrospective registry-based cohort study. Methods: 113 MEN1 patients (51 males) treated at Oulu University Hospital between 1982 and 2023, with an average follow-up of 56 patient-years, were compared to a local control population ( Results: Seven women with MEN1 (11.5%) had breast cancer (BC), 7 (6.2%) with papillary thyroid carcinoma (PTC), and 5 (4.4%) with renal cancers (RC). The mean age at BC diagnosis was 49 years compared to 60 in the general Finnish population. The hazard ratio (HR) for BC in female MEN1 patients was 3.79 (95% CI: 1.66-8.60) compared to controls. Pathogenic variants in established BC risk genes were not present in our MEN1 patients. The HR for PTC and RC were 9.37 (3.59-24.41) and 7.80 (2.74-22.25), respectively. Conclusion: This study demonstrates a significantly increased prevalence of BC, PTC, and RC in MEN1 patients compared to the Finnish general population. The findings support earlier BC screening in women with MEN1 and highlight the need for further research into non-neuroendocrine cancer risks in these patients.

Indexed as

breast cancerMEN1MEN1 genemeninrenal cancerthyroid cancer

Identifiers

PMID41994491
PMCPMC13080203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.